Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 3 institutions in 1 country.
Amanda Aparecida Ribeiro AndradeInstitute of Biomedical Sciences, Federal University of Alfenas, Alfenas 37130-001, MG, Brazil.
Fernanda PauliInstitute of Chemistry, Fluminense Federal University, Niterói 24020-140, RJ, Brazil.
Carolina Girotto PresseteInstitute of Biomedical Sciences, Federal University of Alfenas, Alfenas 37130-001, MG, Brazil.
Bruno ZavanInstitute of Biomedical Sciences, Federal University of Alfenas, Alfenas 37130-001, MG, Brazil.ORCID 0000-0002-3042-8804
João Adolfo Costa HanemannSchool of Dentistry, Federal University of Alfenas, Alfenas 37130-001, MG, Brazil.ORCID 0000-0002-3865-905X
Marta MiyazawaSchool of Dentistry, Federal University of Alfenas, Alfenas 37130-001, MG, Brazil.ORCID 0000-0001-8529-2441
Rafael FonsecaInstitute of Biomedical Sciences, Federal University of Alfenas, Alfenas 37130-001, MG, Brazil.
Ester Siqueira CaixetaInstitute of Biomedical Sciences, Federal University of Alfenas, Alfenas 37130-001, MG, Brazil.
Julia Louise Moreira NacifInstitute of Biomedical Sciences, Federal University of Alfenas, Alfenas 37130-001, MG, Brazil.
Alexandre Ferro AissaInstitute of Biomedical Sciences, Federal University of Alfenas, Alfenas 37130-001, MG, Brazil.ORCID 0000-0002-0759-4011
Eliezer J BarreiroLaboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro 21941-914, RJ, Brazil.ORCID 0000-0003-1759-0038
Marisa IontaInstitute of Biomedical Sciences, Federal University of Alfenas, Alfenas 37130-001, MG, Brazil.ORCID 0000-0001-8796-1426
Universidade Federal de Alfenas · BRUniversidade Federal do Rio de Janeiro · BRUniversidade Federal Fluminense · BR
Funding
Coordenação de Aperfeicoamento de Pessoal de Nível Superior code 001Fundação de Amparo à Pesquisa do Estado de Minas Gerais #APQ- 01164-17Fundação de Amparo à Pesquisa do Estado de Minas Gerais #APQ-02036-21National Council for Scientific and Technological Development #465.249/2014-0
6 · The paper itself
Abstract
Liver cancer is the second leading cause of cancer-related death in males. It is estimated that approximately one million deaths will occur by 2030 due to hepatic cancer. Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer subtype and is commonly diagnosed at an advanced stage. The drug arsenal used in systemic therapy for HCC is very limited. Multikinase inhibitors sorafenib (Nexavar
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Antiproliferative Activity of · full record | OpenQuestion